1. Inflammation/Immunology

Inflammation/Immunology

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-148304
    VU6036720 3026597-12-3 99.89%
    VU6036720 is a potent and specific in vitro inhibitor of Kir4.1/5.1. VU6036720 can inhibit Kir4.1/5.1 channels with an IC50 value of 0.24 μM. VU6036720 can be used for the research of brain and kidney.
    VU6036720
  • HY-148682
    18β-Glycyrrhetyl-3-O-sulfate 10251-38-4 98%
    18β-Glycyrrhetyl-3-O-sulfate (Glycyrrhetic acid 3-O-(hydrogen sulfate)) is a potent type 2 11β-hydroxysteroid dehydrogenase (11β-HSD2) inhibitor with an IC50 of 0.10 µM using rat kidney microsome. 18β-Glycyrrhetyl-3-O-sulfate is the major metabolite of Glycyrrhetinic acid (GA). 18β-Glycyrrhetyl-3-O-sulfate is the substrate of organic anion transporter (OAT) 1 and OAT3. 18β-Glycyrrhetyl-3-O-sulfate has anti-inflammatory effects and has the potential for pseudohyperaldosteronism research.
    18β-Glycyrrhetyl-3-O-sulfate
  • HY-148802
    Taplucainium chloride 2489565-37-7 98.0%
    Taplucainium chloride is a sodium channel blocker. Taplucainium chloride selectively inhibits nociceptors in an activated or inflammatory state. Taplucainium chloride may be used in research on chronic cough.
    Taplucainium chloride
  • HY-149202
    UT-11 98.25%
    UT-11 is a potent and blood-brain barrier-permeable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor with IC50s of 0.10 μM and 2.00 μM for inhibiting PGE2 production in human (SK-N-AS) and murine (BV2) cells, respectively.
    UT-11
  • HY-14928A
    Lobeglitazone sulfate 763108-62-9 99.63%
    Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate is the orally active agonist for PPAR with EC50 of 137.4 nM and 546.3 nM for PPARγ and PPARα. Lobeglitazone sulfate is the inhibitor for ERK/JNK/Smad/NF-κB signaling pathway. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties.
    Lobeglitazone sulfate
  • HY-149391
    PROTAC BTK Degrader-6 2767204-39-5 99.24%
    PROTAC BTK Degrader-6 (Compound 15) is a PROTAC BTK degrader (DC50: 3.18 nM. PROTAC BTK Degrader-6 has anti-inflammatory activity, inhibits NF-κB activation, and inhibits the expression of pro-inflammatory cytokines (e.g. IL-1β, IL-6).
    PROTAC BTK Degrader-6
  • HY-149604
    NLRP3-IN-21 2956791-61-8 98.97%
    NLRP3-IN-21 (compound L38) is a NLRP3 inflammasome inhibitor with inflammatory properties. NLRP3-IN-21 inhibits NLRP3 inflammasome activation and pyroptosis by suppressing gasdermin D cleavage, ASC oligomerization, and NLRP3 inflammasome assembly.
    NLRP3-IN-21
  • HY-150059
    P2X7 receptor antagonist-2 851269-75-5 98.95%
    P2X7 receptor antagonist-2 is a potent P2X7 receptor antagonist with a pIC50 value of 6.5-7.5. P2X7 receptor antagonist-2 has efficacy of combating neuroinflammation.
    P2X7 receptor antagonist-2
  • HY-150235
    Galectin-8N-IN-1 2667628-25-1 98.09%
    Galectin-8N-IN-1 (compound 19a) is a potent and selective galectin-8N inhibitor with a Kd value of 1.8 μM. Galectin-8N-IN-1 is a galectin-8N ligand. Galectin-8N-IN-1 can be used in research of immune system.
    Galectin-8N-IN-1
  • HY-150579
    Keap1-Nrf2-IN-13 2456294-92-9
    Keap1-Nrf2-IN-13 is a Keap1-Nrf2 protein–protein interaction (PPI) inhibitor with an IC50 value of 0.15 μM. Keap1-Nrf2-IN-13 has strong binding affinities to the Keap1 protein by forming hydrogen bond with the key polar residues (Asn414, Arg415, Arg483, Gln530). Keap1-Nrf2-IN-13 can be used in the research of oxidative stress-related and inflammatory diseases, including pulmonary fibrosis, chronic obstructive pulmonary disorder (COPD) and cancers.
    Keap1-Nrf2-IN-13
  • HY-150735
    IRAK4-IN-20 1931994-80-7
    IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research.
    IRAK4-IN-20
  • HY-151115
    JNJ-1289 792898-18-1 98.06%
    JNJ-1289 is a potent, selective, competitive and allosteric human spermine oxidase (hSMOX) inhibitor (IC50: 50 nM). JNJ-1289 can be used in the research of polyamine catabolism, inflammation and cancers.
    JNJ-1289
  • HY-151365
    IRAK4-IN-22 2170694-05-8 99.44%
    IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis.
    IRAK4-IN-22
  • HY-151537
    Gol-NTR 2968461-58-5 99.44%
    Gol-NTR is a Golgi-targetable probe with high selectivity and sensitivity. Gol-NTR is Nitroreductase (NTR)-activated and has visualization acute lung injury (ALI) and repair function. Gol-NTR has a low detection limit of 54.8 ng/mL. Gol-NTR can be used for the research for monitoring and assessing research response of sepsis-induced ALI.
    Gol-NTR
  • HY-153077
    PFKFB3-IN-2 794552-84-4
    PFKFB3-IN-2 is a 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) inhibitor. PFKFB3-IN-2 has potential applications in cancer, neurodegenerative diseases, autoimmune diseases, inflammatory diseases, multiple sclerosis, metabolic diseases, angiogenesis inhibition and other diseases.
    PFKFB3-IN-2
  • HY-153224
    GLPG2534 2095615-97-5 98.73%
    GLPG2534 is an orally active and selective IRAK4 inhibitor, with IC50 values of 6.4 nM and 3.5 nM for human and mouse IRAK4. GLPG2534 can be used for the research of inflammatory skin diseases.
    GLPG2534
  • HY-153935
    EP4-IN-1 2455480-28-9 99.94%
    EP4-IN-1 is a potent prostanoid EP4 receptor inhibitor. EP4-IN-1 is extracted from patent WO2023025270 (example 1), and exhibits prospect in tumor immunity and anti-inflammatory analgesia research.
    EP4-IN-1
  • HY-153999
    Rondaptivon pegol 2573048-75-4 98.20%
    Rondaptivon pegol (BT200) is an aptamer targeting von Willebrand factor (VWF), with an EC50 of 33 nM in humans. Rondaptivon pegol effectively alleviates acute myocardial ischemia-reperfusion injury in mice by inhibiting VWF activity, reducing microvascular obstruction, inflammatory responses and cardiomyocyte apoptosis (apoptosis). Rondaptivon pegol inhibits the binding of VWF to platelet glycoprotein GPIb, thereby preventing arterial thrombosis in cynomolgus monkeys. Rondaptivon pegol can be used in research related to arterial thrombosis, stroke, myocardial infarction and myocardial ischemia-reperfusion injury.
    Rondaptivon pegol
  • HY-155342
    A3373 2324948-66-3 99.57%
    A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with IC50 of 325 nM and 15.15?μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis.
    A3373
  • HY-155463
    NLRP3-IN-25 2660230-90-8 99.78%
    NLRP3-IN-25 (compound 32) is an orally available NLRP3 inhibitor with anti-inflammatory activity. NLRP3-IN-25 attenuates renal injury in doxorubicin-induced glomerulonephritis in mice. NLRP3-IN-25 inhibits IL-1β secretion in THP-1 cells with an IC50 of 21 nM.
    NLRP3-IN-25
Cat. No. Product Name / Synonyms Application Reactivity